Trial · NCT04822337
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
NCT04822337, Phase 1, Phase 2, Recruiting, Wake Forest University Health Sciences
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma. Trials, record NCT04822337. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04822337
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
- NCT number
- NCT04822337
- Status
- Recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 70 participants, estimated
- Lead sponsor
- Wake Forest University Health Sciences
- Conditions
- Multiple Myeloma
- Interventions
- Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin
- First posted
- 2021-03-30
- Last updated
- 2026-10-26
Source ClinicalTrials.gov
Registered outcomes22
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Establish Maximum Tolerated Dose (MTD) | time to complete Cycle 1 (28 days) | DLTs will be determined for each subject enrolled in Phase I as a binary variable indicating whether the subject experienced a DLT during Cycle 1 of belantamab mafodotin-containing protocol directed induction therapy. |
| Primary | Evaluate Complete Response (CR) | up to 5 years | CR will be determined for each subject as a binary variable indicating whether the achieved a best overall response to induction therapy of CR or better. |
| Secondary | Complete Response (CR) | Up to 5 years | CR will be determined for each subject as a binary variable indicating whether the achieved a best overall response to induction therapy of CR or better |
| Secondary | Best Response | Up to 5 years | The best overall response will be determined as an ordered categorial variable indicating the subject's best response at any point along the treatment continuum. |
| Secondary | Very Good Partial Response (VGPR) | up to 5 year | will be determined for each subject as a binary variable indicating whether the achieved a best overall response to induction therapy of VGPR or better. |
| Secondary | Overall Response | up to 5 years post treatment discontinuation | The best overall response will be determined as an ordered categorial variable indicating the subject's best response at any point along the treatment continuum |
| Secondary | MRD Negative | Up to 5 years | . Minimal residual disease (MRD) (via NGF 10-5 and 10-6) will be determined for each subject after suspected CR for Phase I subjects and at the following timepoints for Phase II subjects: after induction therapy, after ASCT, and after 12 cycles of maintenance therapy (post Cycle 18visit) and every 12 months post Cycle 18 sample. |
| Secondary | Time to First Response (TTFR) | up to 30 days post treatment discontinuation | TTFR will be calculated for all subjects achieving an sCR, CR, VGPR, or PR. This will be defined as the time from initiation of belantamab mafodotin-containing protocol directed induction therapy to the time of first disease assessment indicating either sCR, CR, VGPR or PR |
| Secondary | Time to Best Response (TTBR) | up to 30 days post treatment discontinuation | Time to best response will be calculated for all subjects achieving an sCR, CR, VGPR or PR. This will be defined as the time from initiation of belantamab mafodotin-containing protocol directed induction therapy to the time of best disease assessment indicating either sCR, CR, VGPR or PR. |
| Secondary | Time to Progression (TTP) | Up to 5 years | TTP is defined as the duration of time from enrollment to the study (treatment start date) to first occurrence of progressive disease |
1 to 10 of 22Source ClinicalTrials.gov
See all 22 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 41719502 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04822337
GET https://conductscience.org/api/trials/v1/NCT04822337/registered?page=2